Ships within 24 hours on business days · +10% with Bank Pay

Cagrilintide

Shop

Cagrilintide · Research brief

Original Cagrilintide: Structure, Sequence and Timeline

60 WORDS

Short answer

The original cagrilintide molecule is young by pharmaceutical standards. It entered the public scientific record toward the end of the 2010s under a development code, acquired its international nonproprietary name shortly afterward, and became a widely discussed research peptide through the early 2020s, which makes it roughly six to eight years old as a named, publicly described compound as of…

The original cagrilintide molecule is young by pharmaceutical standards. It entered the public scientific record toward the end of the 2010s under a development code, acquired its international nonproprietary name shortly afterward, and became a widely discussed research peptide through the early 2020s, which makes it roughly six to eight years old as a named, publicly described compound as of 2026. The science underneath it is far older: the native hormone it imitates, amylin, was identified in pancreatic amyloid deposits in the mid to late 1980s, and the first engineered amylin analogue reached clinical use in the mid-2000s. In other words, the compound is a recent molecule built on four decades of accumulated peptide chemistry. This page covers what is publicly established about its structure, how its sequence is described, why it carries a fatty acid chain, what the acetate salt form means for laboratory material, and where the public record stops.

How long has cagrilintide been around?

As a named molecule, cagrilintide has been around since the late 2010s, which is approximately six to eight years at the time of writing in 2026. The timeline falls into distinct layers, and keeping them separate avoids a common confusion in which the age of amylin research gets mistaken for the age of this particular analogue.

The first layer is the native hormone. Islet amyloid polypeptide, now usually called amylin, was characterised from amyloid material in pancreatic tissue during the 1980s. That work established a 37-residue hormone co-secreted with insulin from pancreatic beta cells, with a disulfide bridge near the N-terminus and an amidated C-terminal tyrosine. The second layer is the first generation of analogues. Human amylin is notoriously prone to self-association and fibril formation, which makes it difficult to formulate, so medicinal chemists produced substituted variants designed to stay soluble. The best known of these reached the clinic in the mid-2000s and demonstrated that an amylin receptor agonist could be produced as a stable pharmaceutical peptide.

The third layer is the hybrid and long-acting generation. Through the 2000s and 2010s, research groups explored peptides that borrowed structural elements from both amylin and calcitonin, a related hormone that binds the same receptor core. These dual amylin and calcitonin receptor agonists, usually abbreviated DACRAs in the literature, were designed for higher potency and longer persistence. The molecule now called cagrilintide belongs to that generation and was described in development materials under the code AM833 before its nonproprietary name was assigned.

The fourth layer is the clinical and catalog era of the 2020s, when the compound appeared in published obesity-related clinical research, including studies that paired it with the acylated GLP-1 analogue semaglutide, and when research-grade material began appearing in laboratory supply catalogs. Anyone asking how long the compound has existed should answer with the fourth layer for the molecule itself and the first layer for the biology.

What is cagrilintide and what class of molecule does it belong to?

It is a long-acting, lipidated analogue of the pancreatic hormone amylin, described in the literature as a dual amylin and calcitonin receptor agonist. Three descriptors stack together in that sentence, and each one corresponds to a specific piece of molecular design.

Analogue of amylin means the backbone is derived from the native 37-residue hormone rather than invented from scratch. The native peptide is released alongside insulin after nutrient intake, and research describes it as a satiation signal acting in part through receptor populations in the hindbrain, particularly the area postrema, a region outside the tight blood-brain barrier. Studies also report effects on the rate at which the stomach empties and on glucagon signalling in preclinical and clinical models. Those are physiological descriptions from the published amylin literature, not statements about any outcome in a person using a product.

Dual amylin and calcitonin receptor agonist refers to receptor pharmacology. Amylin receptors are not standalone proteins. They are assemblies of the calcitonin receptor with receptor activity modifying proteins, so a peptide shaped partly like amylin and partly like calcitonin can engage both the calcitonin receptor alone and the amylin receptor complexes. DACRA design exploits that overlap deliberately.

Lipidated, or acylated, means a fatty acid chain has been attached to a side chain on the peptide. This is the same half-life extension logic used in several modern peptide therapeutics: the chain binds reversibly to circulating albumin, which slows renal filtration and enzymatic breakdown and lets a peptide persist far longer than a native hormone that is cleared within minutes.

Taken together, the compound is best understood as a native hormone scaffold that has been stabilised against aggregation, tuned for receptor engagement, and anchored to albumin by a lipid chain. Real Peptides supplies the compound strictly as a research-use-only material for laboratory work, and the cagrilintide compound page lists its catalog details.

What does the cagrilintide sequence actually look like?

The sequence is described in the public record as an acylated amylin analogue built on the 37-residue architecture of the native hormone, retaining the N-terminal disulfide loop formed between the two cysteine residues near the start of the chain, ending in an amidated C-terminal residue, and carrying substitutions at several positions that reduce the aggregation tendency of human amylin. A lysine side chain within the chain serves as the attachment point for the lipid.

This page does not reproduce a one-letter sequence string, and the reason is practical rather than evasive. Strings circulating on secondary web pages for this compound are not consistent with one another, and a sequence that is confidently wrong is more damaging to a research record than an honest description of the architecture. The authoritative sources are the originator's medicinal chemistry publication record and the World Health Organization international nonproprietary name documentation, which publishes structural definitions for peptide INNs including modifications. A laboratory that needs the exact residue-by-residue string, the exact position of the acylation site, or the exact linker composition should take it from those primary records and confirm it against lot-level mass spectrometry rather than from a catalog description.

There is a second, deeper reason a plain string is an incomplete description. A one-letter sequence cannot express an intramolecular disulfide bond, a C-terminal amide, or a side-chain acyl modification. Three different molecules can share an identical letter string and differ enormously in mass, charge, solubility and receptor behaviour depending on whether the cysteines are bridged, whether the C-terminus is a free acid or an amide, and whether the lysine is lipidated. For this family of peptides, the modifications are not decorative; the disulfide loop constrains the N-terminal region that drives receptor activation, the C-terminal amide is characteristic of the native hormone, and the acyl chain is the entire basis of the extended duration. A complete structural description therefore needs four elements: the residue sequence, the disulfide connectivity, the C-terminal state, and the identity and attachment point of the lipid.

How does the structure differ from human amylin and pramlintide?

It differs from native human amylin by multiple substitutions plus a lipid chain, and it differs from the earlier amylin analogue pramlintide by both the nature of those substitutions and the presence of acylation. The comparison is the clearest way to see what three generations of design were trying to solve.

Native human amylin has a structural liability. Its mid-chain region is strongly amyloidogenic, meaning the peptide readily stacks into beta-sheet fibrils. That property is central to the islet amyloid seen in pancreatic tissue in type 2 diabetes research, and it also makes the native sequence unmanageable as a pharmaceutical substance, because a peptide that aggregates in a vial is a peptide with unpredictable potency. Rodent amylin, by contrast, resists fibrillation, and the difference traces to a short stretch of residues where proline substitutions break the sheet-forming geometry.

The first-generation analogue exploited exactly that observation, importing proline residues into the human sequence to produce a soluble, non-fibrillating peptide that still activated amylin receptors. It solved aggregation but not duration; it remained a short-lived peptide cleared quickly from circulation.

The generation that includes the present compound went further. Public descriptions characterise it as an amylin analogue with substitutions drawn from the wider calcitonin family alongside stability-oriented changes, producing a molecule that is simultaneously less aggregation-prone, more persistent, and active at both calcitonin and amylin receptor complexes. On top of the sequence changes sits the lipid chain, which addresses duration rather than stability. Research suggests the combination of sequence hardening and albumin anchoring is what separates a hormone fragment with a half-life measured in minutes from a research peptide with a half-life long enough to support once-weekly study designs.

The limitation of any comparison written at this level is that it is architectural rather than quantitative. Side-by-side receptor potency comparisons, fibrillation kinetics and clearance measurements exist in the primary pharmacology literature, and specific numbers should be taken from those papers rather than from a summary page.

Why is the molecule lipidated, and what does the fatty acid chain do?

The fatty acid chain exists to make the peptide bind reversibly to serum albumin, which slows its clearance and extends how long it circulates. This is one of the most widely used half-life extension strategies in modern peptide chemistry, and the general approach is documented in the published discovery account of the acylated GLP-1 analogue semaglutide, Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide, which describes attaching a fatty diacid to a peptide through a hydrophilic spacer so that albumin affinity is high enough to extend residence time without permanently blocking receptor engagement.

The mechanism has several parts. Albumin is the most abundant protein in plasma and is itself long-lived, partly because it is recycled through the neonatal Fc receptor pathway rather than being filtered and degraded. A peptide that spends most of its time bound to albumin is effectively hidden from glomerular filtration, because the complex is far too large to pass the filtration barrier, and it is partly shielded from circulating peptidases. Binding must be reversible, since only the free fraction can reach and activate receptors, so the chemistry aims for an equilibrium rather than a permanent conjugate.

The design variables are the length and chemistry of the lipid and the composition of the spacer that connects it to the peptide. Longer chains and diacid terminal groups generally increase albumin affinity. Hydrophilic spacers, often built from gamma-glutamic acid and short polyethylene glycol-like units, hold the lipid away from the peptide backbone so that the receptor-binding surface is not obstructed and so that the acylated peptide remains soluble rather than behaving like a detergent. Attachment is typically through the epsilon amino group of a lysine side chain, because that group is nucleophilic, accessible and easy to target selectively during synthesis.

The practical consequence for a laboratory is that an acylated peptide does not behave like an unmodified one. It is more surface-active, more inclined to adsorb to plastics and glass, and its apparent behaviour in a binding assay can shift substantially depending on whether albumin or serum is present in the buffer. Published pharmacology for albumin-binding peptides consistently notes this; in vitro potency measured in albumin-free conditions is not directly comparable to potency measured in serum-containing media.

What is cagrilintide acetate, and why is the acetate salt form used?

Cagrilintide acetate is the compound isolated as its acetate salt, meaning acetate ions serve as the counterions balancing the positive charges on the peptide. Nearly all research-grade synthetic peptides containing basic residues are supplied as salts, and acetate is the most common choice for material intended for biological work.

The chemistry is straightforward. A peptide with lysine, arginine or histidine side chains carries net positive charge at the pH values used in purification and storage, and those charges must be balanced. Reversed-phase high performance liquid chromatography, the standard final purification step for synthetic peptides, is usually run with trifluoroacetic acid as the ion-pairing agent, so the peptide that comes off the column is initially a trifluoroacetate salt. Trifluoroacetate is a poor counterion for biological assays: it is reported in the literature to interfere with cell viability and function at concentrations that can accompany a peptide sample, and it is not volatile enough to simply evaporate away. Manufacturers therefore perform a counterion exchange, typically by ion exchange chromatography or by repeated lyophilisation from dilute acetic acid, converting the material to the acetate form.

Acetate has two advantages. It is biologically innocuous at the quantities involved, being a normal metabolic intermediate, and acetic acid is volatile, so excess can be removed during lyophilisation. The result is a lyophilised powder in which acetate is present both as the bound counterion and often as a small amount of residual free acetic acid, which is why freshly opened vials of acetate-salt peptides sometimes carry a faint vinegar-like odour.

Other salt forms exist. Hydrochloride salts are used for some peptides, and formulated pharmaceutical products may use entirely different buffer and excipient systems that have nothing to do with the research powder. The salt form belongs on the certificate of analysis alongside the identity and content data, and Real Peptides publishes independent third-party certificates of analysis for every batch at /coas/ so that the documented identity of a lot can be checked before it is used.

How does cagrilintide acetic acid content affect laboratory work?

Residual acetic acid and bound acetate add mass to the powder that is not peptide, which means the gross mass in a vial is not the same as the mass of the molecule itself. This is the single most practically important consequence of the salt form, and it affects any calculation a laboratory performs.

A lyophilised peptide salt typically contains three non-peptide components: counterion, residual solvent, and adsorbed water, since peptide powders are hygroscopic. The combined contribution is not trivial for a molecule of this size carrying multiple basic residues. Analytical laboratories quantify counterion content by ion chromatography or by quantitative nuclear magnetic resonance, and water content by Karl Fischer titration. Peptide content, distinct from chromatographic purity, is measured by amino acid analysis or by nitrogen determination. Purity and content answer different questions: purity describes what fraction of the peptide-related material is the target molecule, and content describes what fraction of the powder is peptide at all.

Real Peptides does not provide preparation, handling or use guidance for this or any catalog compound, because these are research-use-only materials and such guidance would be protocol advice rather than chemistry education. What can be explained is the framework researchers use: concentration is mass of compound per unit volume of solvent, expressed in milligrams per millilitre, and every downstream calculation derives from that relationship. Where the goal is precise molar concentration rather than nominal mass concentration, the correct denominator is the peptide content from the certificate of analysis and the molecular weight of the free peptide, not the gross powder mass and not the molecular weight of the salt. Studies in analytical peptide chemistry consistently note that ignoring counterion and moisture mass is a common source of apparent potency discrepancies between laboratories working with the same compound.

Which receptors does the molecule engage, and why does its structure matter for that?

It engages the calcitonin receptor and the amylin receptor complexes built from that same receptor, which is why the literature classifies it as a dual agonist. The structural logic follows directly from how amylin receptors are assembled.

The calcitonin receptor is a class B G protein-coupled receptor. When it associates with one of three receptor activity modifying proteins, usually abbreviated RAMP1, RAMP2 and RAMP3, its pharmacology changes and it becomes an amylin receptor, conventionally labelled AMY1, AMY2 and AMY3. The accessory protein does not simply chaperone the receptor to the surface; it contributes to the ligand binding surface, which is why amylin binds the complexes with much higher affinity than it binds the bare calcitonin receptor. Calcitonin itself binds the bare receptor well and retains activity at the complexes.

A peptide that carries structural features of both hormones can therefore activate both the bare receptor and the complexes. Class B GPCR activation follows a two-domain model: the C-terminal portion of the peptide binds the large extracellular domain of the receptor, providing affinity, and the N-terminal portion inserts into the transmembrane bundle, providing activation. For amylin-family peptides, the disulfide-constrained N-terminal loop is part of that activating segment, which is why the loop is retained in engineered analogues rather than simplified away, and the C-terminal amidated region contributes to extracellular domain binding.

Research suggests the functional consequence of dual engagement is a different signalling profile from a pure amylin receptor agonist, including differences in how quickly receptors desensitise after prolonged exposure. Those comparisons are made in cell systems expressing defined receptor combinations, and the usual limits apply: recombinant cell lines overexpress receptors, RAMP stoichiometry in a transfected cell may not match native tissue, and results measured without albumin in the buffer may not translate directly to an acylated peptide that is largely albumin-bound in circulation.

How has the molecule been studied alongside semaglutide?

It has been studied as a co-formulated partner for semaglutide, an acylated GLP-1 receptor agonist, on the rationale that amylin and GLP-1 pathways are separate signalling routes that converge on overlapping physiology. The two peptides remain distinct molecules; they are not covalently joined, and the combination is a mixture rather than a single hybrid compound.

The rationale rests on established GLP-1 pharmacology. Research on semaglutide in adults with overweight or obesity, reported in Once-Weekly Semaglutide in Adults with Overweight or Obesity, describes reductions in body weight relative to placebo across a trial in which participants received assigned trial amounts after a step-up phase, alongside gastrointestinal effects as the most frequently reported adverse events. That trial studied semaglutide alone and says nothing directly about the amylin analogue, but it establishes the comparator against which combination research is interpreted.

The structural point worth making on a chemistry page is that both molecules use the same half-life extension principle. Both are acylated peptides that bind albumin reversibly, which is what makes a shared study design practical in the first place: two peptides with comparable persistence can be studied on the same schedule. The medicinal chemistry precedent for the acylation approach is documented in the semaglutide discovery record cited earlier, and the amylin analogue applies the same strategy to a completely different receptor family.

The limits here are important. Combination research results belong to the named clinical publications that report them, and specific figures should be read in those papers rather than summarised second-hand. Research-grade material supplied for laboratory work is not a clinical product, and nothing in the clinical record describes what happens in non-clinical experimental systems.

What is known about the discovery history and the naming of the compound?

What is publicly known is that the molecule emerged from a pharmaceutical obesity research program in the second half of the 2010s, appeared in early development materials under the code AM833, and was later assigned the international nonproprietary name cagrilintide. The naming itself follows a recognisable convention.

International nonproprietary names are assigned through a World Health Organization process using defined stems. The suffix tide marks a peptide, and the internal elements of the name signal family relationships; names in the amylin analogue family share recognisable fragments with the native hormone and with earlier analogues. An INN application for a modified peptide includes the full structural definition, which is why INN documentation is a legitimate primary source for sequence and modification details when a medicinal chemistry paper is not accessible.

The development code and the nonproprietary name refer to the same molecule, and both are distinct from any brand name attached to a formulated product. Catalog listings, patent documents and registry entries may use any of these identifiers, which is one reason verification by CAS number and molecular identity matters more than matching a name string.

The discovery history also has an intellectual lineage worth recording. The decision to build a dual amylin and calcitonin receptor agonist rather than a pure amylin mimetic came out of the observation that calcitonin-family peptides activate the shared receptor core with different kinetics, and the decision to acylate came out of a decade of successful albumin-binding peptide design in the incretin field. Neither idea was novel in isolation; the compound represents their combination applied to amylin biology.

What the public record does not clearly specify is the internal selection history: how many analogues were screened, what the rejected candidates looked like, and what criteria decided the final structure. Those details sit in unpublished development documentation, and any specific claim about them should be treated as unsourced.

What stability and handling factors does peptide chemistry describe for this family?

The peptide chemistry literature describes four degradation routes that matter for amylin-family analogues: disulfide instability, deamidation, oxidation and aggregation. These are general properties of the chemistry rather than compound-specific measurements, and they explain why lot documentation and controlled storage conditions matter.

Disulfide bonds can scramble or reduce, particularly in solution at neutral to alkaline pH or in the presence of reducing agents. Because the N-terminal loop in this family is formed by a single disulfide and because that loop participates in receptor activation, loss or rearrangement of the bridge changes the molecule functionally even though its total mass barely moves, which means mass spectrometry alone will not catch it. Chromatographic methods and reduction-alkylation mapping are the standard checks.

Deamidation affects asparagine and glutamine residues, converting an amide to a carboxylic acid through a succinimide intermediate and adding roughly one mass unit. Amylin-family sequences contain several asparagine residues, so this is a realistic pathway, and it is accelerated at higher pH and higher temperature in solution.

Oxidation affects methionine, tryptophan and to a lesser extent histidine and tyrosine, and is promoted by light, trace metals and peroxide impurities in excipients or solvents.

Aggregation is the historically defining liability of the amylin scaffold. Engineered analogues are specifically designed against it, but acylation introduces its own surface-active behaviour, and acylated peptides are well documented to adsorb to container surfaces and to self-assemble into micelle-like structures above certain concentrations. The consequence is that nominal concentration and actual free peptide concentration can diverge in dilute solutions.

The general principle across all four routes is that a dry, cold, dark lyophilised solid is far more stable than any solution, which is why research peptides are supplied as lyophilised powders in the first place. Real Peptides does not publish preparation protocols, and none of the above should be read as instructions; it is a description of the chemistry that lot-level analytical documentation is designed to monitor.

How can a laboratory confirm it has received the original compound?

Confirmation comes from documentation plus analytics: a batch certificate of analysis that reports identity, content and salt form, a CAS number and molecular identity checked against independent references before procurement, and ideally an in-house orthogonal check.

The identity portion of a certificate normally rests on mass spectrometry, which confirms that the observed molecular mass matches the expected mass of the intended structure including the disulfide, the C-terminal amide and the acyl chain. Mass alone is necessary but not sufficient, since isobaric errors exist, so chromatographic purity data from reversed-phase HPLC accompanies it to show the proportion of the peptide-related material that corresponds to a single main species. Content and counterion data, as discussed above, complete the picture by describing how much of the powder is actually peptide.

CAS registry numbers are useful because they are assigned to specific chemical entities, but researchers should be aware that the free peptide and its acetate salt can carry different registry numbers, and that a number quoted on a web page is only as reliable as its source. Verifying a CAS number and molecular identity against an independent chemical database before procurement is a basic diligence step for any catalog compound.

For laboratories that want an orthogonal check, peptide mapping after reduction and enzymatic digestion confirms sequence regions directly, and amino acid analysis confirms composition. Neither is necessary for routine work, but both are standard when a result is going into a publication and the identity of the material needs to be defensible.

Real Peptides supplies research-use-only compounds and publishes independent third-party certificates of analysis for every batch at /coas/; shipping and facility details are listed on the location page.

What does the public record still not specify about this molecule?

Several things, and naming them is more useful than filling the gaps with plausible-sounding numbers. The honest boundaries of the public record for this compound include structural, pharmacological and manufacturing details.

On structure, there is no widely circulated experimental three-dimensional structure of the acylated peptide bound to an amylin receptor complex that a research page can point to by name. Structural reasoning for this family is largely inferred from class B GPCR structures solved with related ligands, and inference is not the same as a determined structure for this specific molecule.

On chemistry, the exact molecular formula, exact monoisotopic and average masses, and the precise composition of the spacer between the peptide and the lipid are details that belong on lot documentation and in the originator's chemistry record. Figures quoted without a source should not be trusted, and this page deliberately does not state them.

On pharmacology, comparative receptor potency values, binding constants, clearance parameters and half-life figures exist in primary publications, and any specific number needs the citation that produced it. A summary page that quotes a half-life without a source is giving a reader a number with no provenance.

On manufacturing, the synthetic route, whether a given lot came from solid-phase synthesis, recombinant expression or a hybrid approach, and the specific counterion exchange method used are supplier-level and lot-level facts, not published literature. They appear, when they appear at all, on analytical documentation.

Finally, research-grade material is not a clinical product, and the clinical record describes studies in defined populations under defined protocols. Extrapolating from those studies to any other context is outside what the literature supports, and the material discussed here exists for laboratory investigation only.

All compounds discussed on this page are sold for laboratory research use only and are not for human consumption.

References

  • Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015. PMID: 26308095
  • Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021. PMID: 33567185

Questions

As a named molecule, roughly six to eight years. It appeared in the public record in the late 2010s under a development code, received its nonproprietary name shortly after, and became widely studied through the early 2020s. The underlying amylin hormone, by contrast, was characterised in the mid to late 1980s.
It is described publicly as an acylated analogue built on the 37-residue amylin scaffold, retaining the N-terminal disulfide loop, an amidated C-terminus, and substitutions that reduce aggregation, with a lipid chain on a lysine side chain. Exact residue strings should be taken from primary literature or international nonproprietary name documentation.
Because amylin receptors are assemblies of the calcitonin receptor with receptor activity modifying proteins, a peptide carrying structural elements of both hormones can activate the bare calcitonin receptor and the amylin receptor complexes. The literature calls that profile a dual amylin and calcitonin receptor agonist, abbreviated DACRA.
It means the peptide is isolated as its acetate salt, with acetate ions balancing the positive charges on basic residues. Acetate is preferred over trifluoroacetate for biological work because it is metabolically innocuous and volatile, so excess can be removed during lyophilisation. The salt form appears on the certificate of analysis.
Yes. Bound acetate, residual acetic acid and adsorbed water all add mass that is not peptide, so gross powder mass exceeds peptide mass. Precise molar calculations should use the peptide content figure from the certificate of analysis together with the molecular weight of the free peptide rather than gross mass.
The fatty acid chain binds reversibly to serum albumin, which slows renal filtration and enzymatic breakdown and extends circulating residence time. Published medicinal chemistry describes the same strategy for acylated GLP-1 analogues: a fatty diacid attached through a hydrophilic spacer, giving affinity high enough to extend duration without blocking receptor engagement.
No. Real Peptides supplies research-use-only compounds and does not provide preparation, handling or use guidance, because that would be protocol advice. What is available is analytical documentation: independent third-party certificates of analysis for every batch, published at /coas/, covering identity, content and salt form.
Earlier analogues solved the aggregation problem of human amylin, mainly through proline substitutions that block fibril formation, but remained short-lived. This generation adds calcitonin-family structural elements and an albumin-binding lipid chain, producing a peptide described as both more persistent and active across calcitonin and amylin receptor complexes.
Through batch documentation plus analytics: mass spectrometry confirming the expected mass including the disulfide, C-terminal amide and acyl chain, chromatographic purity data, content and counterion figures, and verification of the CAS number and molecular identity against independent references before procurement. Peptide mapping provides an orthogonal sequence check.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now